Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 113(2021) vom: 15. Dez., Seite 125-126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bozzi, Giorgio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 09.12.2021 Date Revised 03.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.10.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332064263 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332064263 | ||
| 003 | DE-627 | ||
| 005 | 20231225214826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.10.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM332064263 | ||
| 035 | |a (NLM)34666164 | ||
| 035 | |a (PII)S1201-9712(21)00806-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bozzi, Giorgio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2021 | ||
| 500 | |a Date Revised 03.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Latency | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Viremia | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Lombardi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Ludovisi, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Muscatello, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Manganaro, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Gori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Bandera, Alessandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 113(2021) vom: 15. Dez., Seite 125-126 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2021 |g day:15 |g month:12 |g pages:125-126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.10.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2021 |b 15 |c 12 |h 125-126 | ||